Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
PLoS One ; 17(7): e0271440, 2022.
Article in English | MEDLINE | ID: mdl-35834520

ABSTRACT

There is no standard birth weight curve for twins in Japan other than a prototype curve based on 1988-1991. Twins have a high perinatal mortality rate than singletons; therefore, we developed a new standard curve for twin birth weight using data from the 1995-2016 Vital Statistics and compared it with previous reports. We used 469,064 cases for analysis, excluding stillbirths and cases with missing values, and created a standard curve using LMS (statistical methods to vary the distribution by using skewness, median, and coefficient of variation) method. In comparison with previous reports, the mean birth weight decreased by 100-200 g. The groups with the lowest neonatal death rates (NDRs) and infant death rates (IDRs) were those with a birth weight of 1,500-2,499 g (NDR: 0.3%, IDR: 0.6%) and those born at 34-36 weeks (NDR: 0.2%, IDR: 0.4%). Compared to these, the IDR was significantly higher in the 2,500-3,999 g group and the 37-39 weeks group (incidence rate ratio (IRR): 1.1 in the 2,500-3,999 g group, IRR: 1.3 in the 37w0d-39w6d group). In particular, the risks of neonatal mortality and infant mortality were higher in infants born at a birth weight above 3,500 g. Infants born at a birth weight above 3,500 g may include recipients of twin-to-twin transfusion syndrome. The most common causes of infant mortality are accidental death and sudden infant death syndrome (SIDS). We considered the possibility that infants treated as healthy newborns and whose mothers were discharged from the hospital without adequate twin care guidance may be more likely to experience unintentional accidents and SIDS at home. The present study suggested that creating a new twin birth weight standard curve and guidance on managing twins at home for full-term and normal birth weight infants may lead to a reduction in infant deaths.


Subject(s)
Sudden Infant Death , Birth Weight , Female , Humans , Infant , Infant Mortality , Infant, Newborn , Japan/epidemiology , Pregnancy , Risk Factors
2.
PLoS One ; 12(2): e0171066, 2017.
Article in English | MEDLINE | ID: mdl-28158216

ABSTRACT

PURPOSE: As the major toxicity induced by pemetrexed plus carboplatin is severe hematologic toxicities, the aim of this study was to determine the risk factors for severe hematologic toxicities in lung cancer patients. METHODS: We retrospectively investigated data from lung cancer patients who had received pemetrexed plus carboplatin, with or without bevacizumab. This observational study was carried out at Ehime University Hospital using electronic medical records dating from July 2009 to March 2015. Severe hematologic toxicities were defined as grade 3 or 4, according to the Common Terminology Criteria for Adverse Events, version 4.0. RESULTS: Forty-two patients were included in the study. The incidence of grade 3 or 4 hematologic toxicities during the first cycle of chemotherapy and during all cycles was 19.0% and 16.1%, respectively. Multivariate time-depend generalized estimating equations logistic regression analysis revealed that regular use of non-steroidal anti-inflammatory drugs (NSAIDs) was significantly associated with an increased risk of severe hematologic toxicities during all cycles (adjusted odds ratio (OR): 8.32, 95% confidence interval (CI): 1.27-54.38; p = 0.03), whereas creatinine clearance of <45 mL/min was not significantly associated with an increased risk of severe hematologic toxicities during all cycles (adjusted OR: 0.91, 95% CI: 0.25-3.34; p = 0.88). CONCLUSIONS: The results suggest that severe hematologic toxicities in patients receiving carboplatin-based pemetrexed may be significantly induced by the inhibition of renal tubular pemetrexed secretion through drug-drug interactions between NSAIDs and pemetrexed rather than through glomerular filtration of pemetrexed, even with moderate to sufficient renal function.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/adverse effects , Carboplatin/therapeutic use , Hematologic Diseases/chemically induced , Lung Neoplasms/drug therapy , Pemetrexed/therapeutic use , Adult , Aged , Aged, 80 and over , Anemia/blood , Anemia/chemically induced , Anemia/pathology , Female , Hematologic Diseases/blood , Hematologic Diseases/pathology , Humans , Leukopenia/blood , Leukopenia/chemically induced , Leukopenia/pathology , Lung Neoplasms/blood , Lung Neoplasms/pathology , Male , Middle Aged , Multivariate Analysis , Neutropenia/blood , Neutropenia/chemically induced , Neutropenia/pathology , Retrospective Studies , Thrombocytopenia/blood , Thrombocytopenia/chemically induced , Thrombocytopenia/pathology , Treatment Outcome
3.
J Neurol ; 253(11): 1490-4, 2006 Nov.
Article in English | MEDLINE | ID: mdl-17041740

ABSTRACT

BACKGROUND: The frontal assessment battery (FAB) test is a composite tool for assessing executive functions related to the frontal lobe. Neuropsychological and blood-flow studies indicate distinct patterns of deterioration of anterior and posterior cortical function in Alzheimer's disease (AD) and subcortical vascular dementia (VD) patients. We predict that the FAB score may be useful for discriminating VD from AD. OBJECTIVE: To evaluate the clinical usefulness of the FAB test for differential diagnosis of AD and VD. METHODS: We compared FAB scores in 25 patients with AD, 27 patients with VD, and 80 age-matched normal control subjects. The AD group was matched for age, education and MMSE score with the VD group. The subtest scores in FAB were also compared among the three groups. RESULTS: The FAB scores were significantly decreased in both the AD and VD groups compared to the control group, and the reduction were greater in the VD group. Among the FAB subtests, mental flexibility (phonological verbal fluency) was the only subtest that significantly discriminated VD from the other two groups. CONCLUSIONS: The FAB test can provide useful information for differentiating AD and VD at the bedside.


Subject(s)
Alzheimer Disease/diagnosis , Dementia, Vascular/diagnosis , Neuropsychological Tests , Aged , Diagnosis, Differential , Humans , Sensitivity and Specificity
4.
J Neuropathol Exp Neurol ; 65(1): 66-77, 2006 Jan.
Article in English | MEDLINE | ID: mdl-16410750

ABSTRACT

In the present study, we investigated the expression of protease-activated receptors (PARs), receptors for thrombin, in substantia nigra pars compacta (SNpc) of Parkinson disease (PD) brains and cultures of human neurons, astrocytes, oligodendrocytes, and microglia as determined by immunocytochemistry and reverse transcriptase-polymerase chain reaction (RT-PCR). Expression of PAR-1 was demonstrated only in glial fibrillary acidic protein-positive astrocytes in SNpc, and the number of astrocytes expressing PAR-1 increased in SNpc of PD as compared with nonneurologic control brain. Immunoreactivity for thrombin and prothrombin was stronger in astrocytes and the vessel walls in SNpc of PD brains. PAR-1 was expressed in human astrocytes and neurons, but not in oligodendrocytes or microglia as determined by RT-PCR. We investigated thrombin-mediated activation of human astrocytes. Thrombin treatment activates human astrocytes and induces morphologic change and a marked increase in proliferation of astrocytes. Increased expression of glial cell line-derived growth factor and glutathione peroxidase (GPx) but no change in the expression of nerve growth factor and inflammatory cytokines/chemokine (IL-1beta, IL-6, IL-8, MCP-1) was found in thrombin/PAR-activated astrocytes. Next, we studied the neuroprotective effect exerted by thrombin-activated astrocytes in human cerebral neuron x human neuroblastoma hybrid neurons. Although thrombin showed neurotoxicity against human hybrid neurons in a dose-dependent manner, the conditioned media derived from thrombin-pretreated astrocyte cultures promoted the survival of human hybrid neurons. The protective effect was completely inhibited with a GPx inhibitor, mercaptosuccinic acid, indicating that GPx released from thrombin/PAR-activated astrocytes is responsible for neuroprotection of hybrid neurons against thrombin cytotoxicity. The present study suggests that the increased expression of PAR-1 in astrocytes in SNpc of PD brain is the restorative move taken by the brain to provide neuroprotection against neuronal degeneration and cell death of dopaminergic neurons caused by noxious insults during the progression of PD pathology.


Subject(s)
Astrocytes/metabolism , Glutathione Peroxidase/physiology , Parkinson Disease/pathology , Receptor, PAR-1/metabolism , Up-Regulation/physiology , Aged , Aged, 80 and over , Astrocytes/drug effects , Case-Control Studies , Cell Survival/drug effects , Cell Survival/physiology , Cells, Cultured , Cytokines/metabolism , Dose-Response Relationship, Drug , Enzyme-Linked Immunosorbent Assay/methods , Female , Glial Fibrillary Acidic Protein/metabolism , Humans , Immunohistochemistry/methods , Male , Nerve Growth Factors/metabolism , Neurons/drug effects , Neurons/metabolism , Parkinson Disease/metabolism , Prothrombin/metabolism , RNA, Messenger/biosynthesis , Receptor, PAR-1/classification , Receptor, PAR-1/genetics , Reverse Transcriptase Polymerase Chain Reaction/methods , Tetrazolium Salts , Thiazoles , Thrombin/metabolism , Thrombin/pharmacology , Time Factors , Up-Regulation/drug effects
5.
J Neurosci Res ; 81(3): 342-8, 2005 Aug 01.
Article in English | MEDLINE | ID: mdl-15957187

ABSTRACT

Microglia are a major neuroglial component of the CNS, playing an important role as resident immunocompetent and phagocytic cells in the CNS in the event of injury and disease. To understand the role of microglia in the CNS in health and diseases, we have recently established an immortalized clonal cell line of human microglia, HMO6, from human embryonic telencephalon tissue by using a retroviral vector encoding v-myc. This immortalized microglia HMO6 cell line exhibits cell-type-specific antigens for microglia, including CD11b (Mac-1), CD68, CD86 (B7-2), HLA-ABC, HLA-DR, and RCA-1 lectin, and actively phagocytoses latex beads.


Subject(s)
Gene Expression Regulation/physiology , Microglia/cytology , Phenotype , Animals , Antigen-Presenting Cells/metabolism , Cell Line , Cell Transplantation , Chemokines/metabolism , Cytokines/metabolism , Humans , Mice , Microglia/physiology
6.
Anal Sci ; 21(4): 361-6, 2005 Apr.
Article in English | MEDLINE | ID: mdl-15844326

ABSTRACT

Lipoylamino-beta- and gamma-cyclodextrin (LP-beta-CD and LP-gamma-CD, respectively) were adsorbed at the surface of gold electrodes by sulfur-gold bonding. The resultant electrodes exhibited quasi-reversible voltammograms for the redox reaction of Fe(CN)6(3-/4-) in aqueous solutions, with peak-to-peak separation (deltaEp) being 85 mV at 20 mV s(-1) as a potential sweep rate. When bile acids are added to the solution, deltaEp values increased to 200-300 mV with increasing the concentration of bile acids. A Langmuir-type adsorption analyses satisfactorily afforded the binding constants (Ksurf) of the surface-confined LP-beta-CD and LP-gamma-CD with the bile acids. The obtained Ksurf values of LP-gamma-CD are 5.0-50 times larger than the corresponding binding constants of gamma-CD in homogeneous aqueous solutions. Cyclic voltammetric experiments with positively, negatively, and non-charged adamantane derivatives as well as pH titration experiments revealed that the retardation of the electrode reaction of negatively charged Fe(CN)6(3-/4-) caused by bile acids was attributable (1) to electric potential changes due to the accumulation of the negative charges at the electrode surface, and (2) to an increase in the hydrophobicity of the electrode surface due to the binding of hydrophobic bile acids to the LP-beta-CD and LP-gamma-CD membranes.


Subject(s)
Bile Acids and Salts/analysis , Cyclodextrins/chemistry , Algorithms , Electrochemistry , Electrodes , Gold , Hydrogen-Ion Concentration , Kinetics , Solutions
SELECTION OF CITATIONS
SEARCH DETAIL
...